vorinostat + gemcitabine + docetaxel

This combination therapy consists of the histone deacetylase (HDAC) inhibitor vorinostat, the antimetabolite gemcitabine, and the taxane docetaxel. It was investigated in a Phase 1b/2 clinical trial (NCT02579785) led by Dr. Melissa Burgess for the treatment of advanced soft tissue sarcomas. Vorinostat is intended to modulate gene expression and potentially sensitize tumor cells to the cytotoxic effects of gemcitabine and docetaxel. Gemcitabine inhibits DNA synthesis by acting as a nucleoside analog and inhibiting ribonucleotide reductase, while docetaxel disrupts microtubule assembly, leading to cell cycle arrest and apoptosis. The regimen also typically includes pegfilgrastim for neutropenia prophylaxis.

Other names

vorinostat + gemcitabine + docetaxelSAHA + gemcitabine + docetaxel